Evidence map›Paper›PMID 28447325›Full record

ArticleClinical journal of gastroenterology2017

Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.

Ayumu Yoshikawa, Katsumi Terashita, Kenichi Morikawa, Soichiro Matsuda, Takahiro Yamamura, Koichiro Sarashina, Shintaro Nakano, Yoshimitsu Kobayashi, Susumu Sogabe, Kazuhiro Takahashi and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Oral lichen planus and HCV infection.Autopsy & case reports · 2020
    Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Ayumu YoshikawaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Katsumi TerashitaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Kenichi MorikawaDivision of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan. kenichi.morikawa@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-3891-5113
Soichiro MatsudaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Takahiro YamamuraDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Koichiro SarashinaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Shintaro NakanoDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Yoshimitsu KobayashiDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Susumu SogabeDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Kazuhiro TakahashiDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Shin HabaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Hisashi OdaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Tatsuro TakahashiCentral Clinical Laboratory, Kushiro Rosai Hospital, Kushiro, Japan.
Takuto MiyagishimaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Naoya SakamotoDivision of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Kushiro Rosai Hospital · JPHokkaido University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection remains the main cause of liver disease and can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV may also develop extrahepatic manifestations in the skin, eyes, joints, kidneys, nervous system, and immune system. In fact, several studies reported that up to 70% of HCV patients experienced extrahepatic manifestations. Lichen planus (LP), which is an immune system disorder that is triggered by viral infections, allergens, and stress, can affect the skin, mouth, nails, and scalp. The association of LP with HCV has been reported, but the effect of HCV treatment on LP remission is controversial. We encountered a 53-year-old man with HCV genotype 2a and LP that were successfully treated with sofosbuvir and ribavirin for 12 weeks. After treatment, he achieved sustained virological response against HCV and remission of erosive LP lesions on the lip. In the era of interferon (IFN)-based treatment for HCV, exacerbation of autoimmune diseases is a common adverse event. Therefore, use of an IFN-free regimen of direct-acting antivirals for HCV might prevent the extrahepatic manifestation of an immune disorder.

Indexed as

Antiviral AgentsDrug Therapy, CombinationGenotypeHepacivirusHepatitis CHumansLichen PlanusLipLip DiseasesMaleMiddle AgedRibavirinSofosbuvirAntiviral AgentsRibavirinSofosbuvirDirect-acting antiviralsExtrahepatic manifestationHepatitis C virusLichen planus

Identifiers

PMID28447325
OpenAlexW2607602933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.